Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables

References

• American Diabetes Association. Data and statistics about diabetes. Arlington, VA, USA: ADA. 2015. Available at: https://professional.diabetes.org/sites/professional.diabetes.org/files/media/fast_facts_12-2015a.pdf
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
   PubMed Web of Science ®Google Scholar
• Tao B, Pietropaolo M, Atkinson M, et al. Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. PLoS One 2010;5:e11501
   PubMed Web of Science ®Google Scholar
• Rowley WR, Bezold C, Arikan Y, et al. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag 2017;20:6-12
   PubMed Web of Science ®Google Scholar
• Department of Health. The pharmaceutical price regulation scheme. London, UK: DoH; 2014. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/282523/Pharmaceutical_Price_Regulation.pdf
   Google Scholar
• Academy of Managed Care Pharmacy. AMCP guide to pharmaceutical payment methods; Alexandria, VA, USA: AMCP. 2013 update. Available at: http://www.amcp.org/pharmaceutical-payment-guide/
   Google Scholar
• American Diabetes Association. Approaches to glycemic treatment. Diabetes Care 2015;38(Suppl 1):S41-S48
   PubMed Web of Science ®Google Scholar
• Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1489-97
   PubMed Web of Science ®Google Scholar
• Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013;30:1293-7
   PubMed Web of Science ®Google Scholar
• Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013;98:1154-62
   PubMed Web of Science ®Google Scholar
• Vora J, Christensen T, Rana A, et al. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther 2014;5:435-46
   PubMed Web of Science ®Google Scholar
• Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA 2017;318:33-44
   PubMed Web of Science ®Google Scholar
• Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA 2017;318:45-56
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17:5-14
   PubMed Web of Science ®Google Scholar
• Medi-Span Price Rx®. Hudson, OH, USA: Wolters Kluwer Clinical Drug Information, Inc. 2016. Available at: https://pricerx.medispan.com
   Google Scholar
• Foos V, Varol N, Curtis BH, et al. Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. J Med Econ 2015;18:420-32
   PubMed Web of Science ®Google Scholar
• Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90
   PubMedGoogle Scholar
• Weatherall J, Buchs S, Bloudek L. Budget impact in the United States with insulin degludec compared to insulin glargine. Presented at the American Diabetes Association 76th Annual Scientific Sessions, June 10–14 2016, New Orleans, LA.
   Google Scholar
• Ward A, Alvarez P, Vo L, et al. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ 2014;17:176-83
   PubMedGoogle Scholar
• Boulin M, Diaby V, Tannenbaum C. Preventing unnecessary costs of drug-induced hypoglycemia in older adults with type 2 diabetes in the United States and Canada. PLoS One 2016;11:e0162951
   PubMed Web of Science ®Google Scholar
• Leiter LA, Boras D, Woo VC. Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals. Can J Diabetes 2014;38:38-44
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
   PubMed Web of Science ®Google Scholar
• Ward A, Alvarez P, Vo L, et al. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ 2014;17:176-83
   PubMedGoogle Scholar
• Yeaw J, Lee WC, Aagren M, et al. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm 2012;18:21-32
   PubMed Web of Science ®Google Scholar
• Li C, Ford ES, Zhao G, et al. Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995–2007. J Diabetes Complications 2012;26:17-22
   PubMed Web of Science ®Google Scholar
• SIX Financial Information. Market data feed. USDGBP exchange rate; April 2017. Available at: https://www.six-financial-information.com/en/shared/offerings/products/data-delivery-products/mdf.html
   Google Scholar
• Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Diabetes Obes Metab 2014;16:366-75
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37
   PubMed Web of Science ®Google Scholar
• SIX Financial Information. Market data feed. USDSEK exchange rate; April 2017. Available at: https://www.six-financial-information.com/en/shared/offerings/products/data-delivery-products/mdf.html
   Google Scholar
• Ryen L, Svensson M. The willingness to pay for a quality adjusted life year: a review of the empirical literature. Health Econ 2015;24:1289-301
   PubMed Web of Science ®Google Scholar
• Ericsson Å, Pollock RF, Hunt B, et al. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ 2013;16:1442-52
   PubMedGoogle Scholar
• Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD. Cost-effectiveness analysis 2.0. N Engl J Med 2017;376:203-5
   PubMed Web of Science ®Google Scholar